Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

523
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.7K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.7K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.4K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.4K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

710
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
710
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

776
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same author

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026
Same author

Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis.

JAMA oncology·2026
Same author

In Vivo Base Editing of <i>PCSK9</i> with VERVE-102 for Hypercholesterolemia.

The New England journal of medicine·2026
Same author

Hepatitis at Home: Ambulatory management of severe immune checkpoint inhibitor related hepatitis.

QJM : monthly journal of the Association of Physicians·2026
Same author

Day-case robotic adrenalectomy under ERAS protocol: early outcomes from a single-centre experience.

World journal of urology·2026

Related Experiment Video

Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Evidence for more intensive cholesterol lowering.

Handrean Soran1, See Kwok, Safwaan Adam

  • 1aDepartment of Medicine, Central Manchester University Hospitals NHS Foundation Trust. bLipoprotein Research Group, Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Core Technology Facility, Manchester, UK.

Current Opinion in Lipidology
|May 17, 2017
PubMed
Summary

Achieving lower LDL cholesterol targets, especially with statins plus ezetimibe or PCSK9 inhibitors, effectively reduces cardiovascular disease (CVD) risk. Treatment intensity should be guided by initial LDL levels and individual CVD risk for optimal outcomes.

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.7K

Related Experiment Videos

Last Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Cardiovascular disease (CVD) risk reduction with cholesterol-lowering drugs correlates with LDL cholesterol decrease.
  • Current guidelines vary on statin dose titration versus non-statin adjunctive therapies due to limited evidence from fixed-dose statin trials.

Purpose of the Study:

  • To compare the effectiveness of different lipid-lowering strategies in reducing CVD events.
  • To evaluate the number of patients needed to treat (NNT) for 10 years to prevent one CVD event across various treatment intensities.

Main Methods:

  • Meta-analysis of 10 randomized controlled trials (75,439 participants) comparing two lipid-lowering intensities.
  • Compared observed NNT with NNT predicted from predominantly single-dose statin trials.
  • Analyzed strategies based on pre-treatment LDL cholesterol levels and target achievement.

Main Results:

  • Observed NNT closely correlated with predicted NNT (Pearson R=0.844, P=0.001), with a mean LDL cholesterol decrease of 0.95 mmol/l.
  • Achieving an LDL cholesterol target of 1.8 mmol/l was most effective when pre-treatment levels exceeded 4 mmol/l.
  • Fixed-dose statin (atorvastatin 80 mg equivalent) was superior at lower pre-treatment LDL levels; a 40% non-HDL cholesterol reduction target was least effective.

Conclusions:

  • When initial LDL cholesterol is >4 mmol/l and CVD risk is high, targeting 1.8 mmol/l is recommended, potentially using ezetimibe and/or PCSK9 inhibitors with statins.
  • Treatment strategies should be individualized based on baseline LDL cholesterol and absolute CVD risk.